Acta Haematol
- JIN X, Jiang X, Li H, Shen K, et al
Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma
and Primary Plasma Cell Leukemia Defined by New Criteria.
Acta Haematol. 2024 Apr 16. doi: 10.1159/000538658.
Ann Hematol
- THAU S, Poulsen CB, Brieghel C, Larsen MK, et al
COVID-19 severity in patients with chronic lymphocytic leukemia treated with
venetoclax: a single-center observational cohort study.
Ann Hematol. 2024 Apr 18. doi: 10.1007/s00277-024-05738.
- JEBANESAN DZP, Illangeswaran RSS, Rajamani BM, Vidhyadharan RT, et al
Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in
FLT3-mutated Acute Myeloid Leukemia.
Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05742.
- LEOTTA S, Markovic U, Duminuco A, Mule A, et al
Impact of minimal residual disease response and of status of disease on survival
after blinatumomab in B-cell acute lymphoblastic leukemia: results from a
real-life study.
Ann Hematol. 2024 Apr 13. doi: 10.1007/s00277-024-05725.
- FRANKE GN, Loewe G, Reiser M, Linde H, et al
Spotlight on the real-world treatment of CML pts in Germany: a retrospective
survey in private oncology practices.
Ann Hematol. 2024;103:1569-1575.
- NISCOLA P, Gianfelici V, Giovannini M, Piccioni D, et al
Very long-term efficacy of venetoclax combined with hypomethylating agents in two
AML elderly: is it the time for treatment discontinuation strategies?
Ann Hematol. 2024;103:1787-1788.
- SHUMILOV E, Mazzeo P, Ghandili S, Kunstner A, et al
Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in
close interaction with therapeutic considerations.
Ann Hematol. 2024;103:1587-1599.
Biochem Biophys Res Commun
- SUZUKI S, Liu J, Sato Y, Miyake R, et al
Fucosylation inhibitor 6-alkynylfucose enhances the ATRA-induced differentiation
effect on acute promyelocytic leukemia cells.
Biochem Biophys Res Commun. 2024;710:149541.
Blood
- WOYACH JA, Perez Burbano G, Ruppert AS, Miller C, et al
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens
for older adults with CLL.
Blood. 2024;143:1616-1627.
- RENGA G, Nunzi E, Stincardini C, Pariano M, et al
CPX-351 exploits the gut microbiota to promote mucosal barrier function,
colonization resistance, and immune homeostasis.
Blood. 2024;143:1628-1645.
- LAMBLE AJ, Rau RE
IFN-gamma and CD38 in AML: a T-cell engagement made in heaven?
Blood. 2024;143:1556-1557.
- CUNEO A, Ghia P
Ibrutinib in CLL: benefit for all?
Blood. 2024;143:1558-1559.
- BUFFET R
How lipid coating soothes the gut in AML therapy.
Blood. 2024;143:1559-1561.
- LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in
the era of targeted therapies.
Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564.
BMC Cancer
- YI X, Zhan H, Lyu J, Du J, et al
A chest CT-based nomogram for predicting survival in acute myeloid leukemia.
BMC Cancer. 2024;24:458.
- WANG L, Zhao S, Wang Y, Liu J, et al
UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/AKT
activation.
BMC Cancer. 2024;24:497.
Bone Marrow Transplant
- SHEN Y, Liu M, Shen D, Chu M, et al
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide
for allogeneic hematopoietic stem cell transplantation in patients with acute T
lymphoblastic leukemia: a large-scale propensity score matching-based study.
Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02280.
- DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al
Safety and efficacy of a new academic CD19-directed CAR-T cell for
refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in
Brazil.
Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283.
- NAGLER A, Labopin M, Swoboda R, Schroeder T, et al
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate
mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and
methotrexate combinations as graft-versus-host disease prophylaxis post
allogeneic stem cell transplanta
Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02284.
Cancer Lett
- SUN H, Xie Y, Wu X, Hu W, et al
circRNAs as prognostic markers in pediatric acute myeloid leukemia.
Cancer Lett. 2024;591:216880.
Int J Hematol
- FUJITA H
JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute
promyelocytic leukemia (APL).
Int J Hematol. 2024 Apr 17. doi: 10.1007/s12185-024-03749.
J Clin Oncol
- TOBIASSON M, Pandzic T, Illman J, Nilsson L, et al
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients
With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell
Transplantation.
J Clin Oncol. 2024;42:1378-1390.
J Virol
- PRAMONO D, Takeuchi D, Katsuki M, AbuEed L, et al
FeLIX is a restriction factor for mammalian retrovirus infection.
J Virol. 2024;98:e0177123.
Leuk Lymphoma
- TINAJERO J, Ngo D, Zhang J, Tsai NC, et al
High remission rates and transition to allogeneic transplant in older patients
with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin
plus intensive chemotherapy.
Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506.
Leuk Res
- HU X, Cao P, Wang F, Wang T, et al
Alternative polyadenylation quantitative trait loci contribute to acute myeloid
leukemia risk genes regulation.
Leuk Res. 2024;141:107499.
- ZAD Z, Bonecker S, Wang T, Zalcberg I, et al
Prediction of deep molecular response in chronic myeloid leukemia using
supervised machine learning models.
Leuk Res. 2024;141:107502.
- BERTON G, Sedaki B, Collomb E, Benachour S, et al
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly
diagnosed acute myeloid leukemia.
Leuk Res. 2024;141:107500.
- ASHOURI K, Ginosyan AA, Chu M, Hom B, et al
Donor matters: Donor selection impact on hematopoietic stem cell transplantation
outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights
from a myeloablative HSCT study.
Leuk Res. 2024;141:107501.
Leukemia
- IYODA S, Yoshida K, Shoji K, Ito N, et al
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute
myeloid leukemia.
Leukemia. 2024 Apr 18. doi: 10.1038/s41375-024-02244.
- NORONHA N, Durette C, Cahuzac M, E Silva B, et al
Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine
in acute myeloid leukemia.
Leukemia. 2024 Apr 16. doi: 10.1038/s41375-024-02250.
- CURIK N, Laznicka A, Polivkova V, Krizkova J, et al
Combination therapies with ponatinib and asciminib in a preclinical model of
chronic myeloid leukemia blast crisis with compound mutations.
Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248.
- MATSUI S, Ri C, Bolanos LC, Choi K, et al
Metabolic reprogramming regulated by TRAF6 contributes to the leukemia
progression.
Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02245.
PLoS One
- KNOPPERS T, Haley CE, Bouhouita-Guermech S, Hagan J, et al
From code to care: Clinician and researcher perspectives on an optimal
therapeutic web portal for acute myeloid leukemia.
PLoS One. 2024;19:e0302156.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016